Skip to main content
. 2014 Jul 17;9(7):e101509. doi: 10.1371/journal.pone.0101509

Figure 2. MiR-15a, -16, -195, and -103 expression in peripheral blood and heart tissue in patients with end-stage HF.

Figure 2

(A) miR-15a, -16, -195, and -103 in peripheral blood were decreased in patients with end-stage HF prior to LVAD implant (pre-LVAD) (n = 9) compared to age, gender, and ethnicity matched healthy controls (n = 6). MiR-16 expression increased from end-stage HF prior to LVAD (HF pre-LVAD, n = 9) compared to patients with end-stage HF 7 days post LVAD (HF 7 days post-LVAD) (n = 9). MiR-15a, -16, -195, and -103 were decreased in patients with HF compared to controls. (B) Expression of miR-15/107 family in heart samples was not significantly different between non-failing controls (Controls) (n = 9) and end-stage HF samples (HF pre-LVAD) (n = 10). Samples were in duplicate and target expression normalized to SnU6 for A and B (mean ±SE).